GC Biopharma USA Highlights Innovative Manufacturing Approach to IVIG Safety at 2025 CIS Annual Meeting

• Differences in manufacturing processes impact the tolerability of intravenous immune globulin (IVIG) products
• GC Biopharma's manufacturing process reduces FXIa to undetectable levels – a critical step in delivering a high-purity IVIG treatment

TEANECK, N.J., June 27, 2025 /PRNewswire/ -- GC Biopharma USA, Inc., a leader in plasma-derived products, announced the presentation of data at the 2025 Clinical Immunology Society (CIS) Annual Meeting by Dr. Ryan Dorfman, Chief Operating Officer of Prolytix. Dr. Dorfman described the clinical and mechanistic consequences of residual activated coagulation Factor XI (FXIa) in intravenous immune globulin (IVIG) therapies, a known contributor to thromboembolic events, and the effectiveness of using cation exchange (CEX) chromatography to reduce FXIa to undetectable levels.

"The presence of even trace amounts of FXIa has been associated with serious thrombotic risks, making its removal a critical safety consideration for IVIG therapies," said Dr. Ryan Dorfman. "Traditional manufacturing processes that rely on ethanol-based fractionation can denature proteins, creating antigenic byproducts as well as activation of both complement and coagulation cascades. Incorporating purification techniques, such as CEX chromatography, may reduce the presence of these trace proteins while maintaining the efficacy of IVIG therapy."

The symposium, titled, "The Impact of Process-Related Contaminants in IVIG on Adverse Patient Events and Tolerability: Exploring the Risks and Mechanisms," was presented by Dr. Dorfman, a paid consultant to GC Biopharma, and a recognized expert in blood coagulation, protein biochemistry, and analytical development.

This symposium reflects GC Biopharma's leadership in advancing industry dialogue around IVIG purity, the clinical impact of process-related contaminants, and the company's ongoing commitment to elevating standards in IVIG manufacturing.

ALYGLO® is approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary humoral immunodeficiency (PI) in adults aged 17 and older. ALYGLO® is supported by GC Biopharma's 50-year legacy in plasma product manufacturing with immune globulin therapies distributed in more than 50 countries worldwide.

For more information about ALYGLO and G-XI™ Technology, visit www.alyglo.com or www.gcbiopharma.us.

About ALYGLO®
ALYGLO® (immune globulin intravenous, human-stwk) is a glycine-stabilized 10% immunoglobulin G (100 mg/mL) for intravenous infusion, manufactured from pooled human plasma from US donors. The manufacturing process includes multiple steps to reduce the risk of virus transmission. These include solvent/detergent treatment and 20 nm nanofiltration. The ALYGLO manufacturing process also uses G-XI™ Technology, its novel cation exchange (CEX) chromatography, that removes FXIa to undetectable levels (References 1,2).

About GC Biopharma
GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers lifesaving and life-sustaining protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Biopharma is a leading global plasma protein and vaccine product manufacturer dedicated to quality healthcare solutions for over half a century.

About GC Biopharma USA
GC Biopharma USA established its sales, marketing, and business operations in 2018 to serve customers and patients throughout the US. Our foundation is built on the expertise of our parent company GC Biopharma, a leading biopharmaceutical company delivering plasma therapies and vaccines worldwide for more than 50 years. With GC Biopharma USA, GC Biopharma further extends its footprint, bringing its expertise and legacy to the US.

Please see Important Safety Information for ALYGLO on the following pages and refer to the full Prescribing Information (PI) or visit Alyglo.com.
If you have an inquiry related to drug safety, or to report adverse events, please contact GC Biopharma USA at 1-833-426-6426 or email [email protected]. You can also visit FDA.gov/medwatch or call 1-800-FDA-1088.

INDICATION
ALYGLO® is indicated for the treatment of primary humoral immunodeficiency (PI) in adults aged 17 years and older. This includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

IMPORTANT SAFETY INFORMATION

• Contraindications: ALYGLO is contraindicated in patients who have a history of anaphylactic or severe systemic reaction to the administration of human immune globulin and in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity.
• Hypersensitivity: In case of hypersensitivity, discontinue infusion immediately and institute appropriate treatment. Epinephrine should be available for immediate treatment of severe acute hypersensitivity reactions.
• Hyperproteinemia, Increased Serum Viscosity, and Hyponatremia: Hyperproteinemia, increased serum viscosity, and hyponatremia may occur.
• Aseptic Meningitis Syndrome (AMS): Aseptic meningitis syndrome (AMS) may occur, especially with high doses or rapid infusion. AMS usually begins within several hours to 2 days following ALYGLO treatment. Discontinuation of treatment has resulted in remission of AMS within several days without sequelae.
• Hemolysis: Delayed hemolytic anemia due to enhanced red blood cell (RBC) sequestration and acute hemolysis consistent with intravascular hemolysis have been reported. Cases of severe hemolysis-related renal dysfunction/failure or disseminated intravascular coagulation have occurred following infusion of IGIV. Closely monitor patients for clinical signs and symptoms of hemolysis, particularly patients with risk factors.
• Transfusion-Related Acute Lung Injury: Noncardiogenic pulmonary edema (transfusion-related acute lung injury [TRALI]) may occur. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Patients with TRALI may be managed using oxygen therapy with adequate ventilator support. Monitor patients for pulmonary adverse reactions.
• Transmissible Infectious Agents: Because ALYGLO is made from human blood, it may carry a risk of transmitting infectious agents (eg, viruses, the variant Creutzfeldt-Jakob disease [vCJD] agent and, theoretically, the Creutzfeldt-Jakob disease [CJD] agent).
• Interference with Laboratory Tests: After infusion of immunoglobulin, the transitory rise of the various passively transferred antibodies in the patient's blood may yield positive serological testing results, with the potential for a misleading interpretation.
• Adverse reactions (observed in ≥ 5% of study subjects) were headache, nausea/vomiting, fatigue, nasal/sinus congestion, rash, arthralgia, diarrhea, muscle pain/aches, infusion site pain/swelling, abdominal pain/discomfort, cough, and dizziness.
• It is recommended that ALYGLO be administered separately from other drugs or medications.

This press release may contain forward-looking statements that express the current beliefs and expectations of the management at GC Biopharma and GC Biopharma USA. Such views do not represent any guarantee by either entity or its government of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma and GC Biopharma USA undertake no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements they may make, except as required by law or stock exchange rule.

Reference: 1. Kang GB, Huber A, Lee J, et al. Cation exchange chromatography removes FXIa from a 10% intravenous immunoglobulin preparation. Front Cardiovasc Med. 2023;10:1253177. 2. ALYGLO Prescribing Information. GC Biopharma; 2023.

SOURCE GC Biopharma USA Inc.